Nurses' Social Representations of Men's Sexual Health Care Access: Preliminary Results.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lust Hannah, Schultz Liora M, Kwon Soyang, Roloff Gregory W, Aldoss Ibrahim, Baggott Christina, John Samuel, Rossoff Jenna E, McNerney Kevin O, Fabrizio Vanessa A, Talano Julie-An, Moskop Amy, Curran Kevin J, Phillips Christine L, Karras Nicole, Baumeister Susanne H C, Cooper Stacy L, Hermiston Michelle, Satwani Prakash, Qayed Muna, Raikar Sunil S, MacMillan Margaret, Hall Erin, Nguyen Khanh, Cassaday Ryan D, Kopmar Noam E, Kota Vamsi K, Mathews John, Shaughnessy Paul, Schwartz Marc S, Ladha Abdullah, Yaghmour George, Kumaran Muthu V, Bachanova Veronika, Tracy Sean, Othman Tamer, Luskin Marlise R, Chen Evan C, Advani Anjani S, Jeyakumar Nikeshan, Miller Katharine, Zhang Amy, Sutherland Katherine C, Shah Bijal D, Muffly Lori, Faramand Rawan
Аннотация
Tisagenlecleucel (tisa-cel) and brexucabtagene autoleucel (brexu-cel) are approved CD19 chimeric antigen receptor T-cell therapy (CAR T) products for young adults (YA) with relapsed/refractory B-cell acute lymphoblastic leukemia. A distinct analysis of YAs receiving commercial CD19 CAR T has not been reported. Using retrospective data from the Pediatric Real-World CAR T Consortium and the Real-World Outcomes of CAR T in Adult ALL collaboration, we describe the efficacy and safety of tisa-cel and brexu-cel in 70 YAs (18-26 years; tisa-cel, n = 50; brexu-cel, n = 20). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were observed more frequently for brexu-cel vs tisa-cel (CRS, 85% vs 56%; ICANS, 40% vs 18%). Complete response rates were similar between products at 80% for brexu-cel and 88% for tisa-cel. Relapse-free survival (RFS) at 12 months was 46% for brexu-cel and 36% for tisa-cel. Durability of remission over 12 months was 61% for brexu-cel vs 41% for tisa-cel; 12-month overall survival (OS) for brexu-cel was 84% vs 68% for tisa-cel. In multivariate analysis, low disease burden was associated with improved OS, whereas inotuzumab before CAR T was associated with inferior outcomes. This study demonstrates comparable real-world efficacy among YAs receiving CD19 CAR T irrespective of CAR T construct; however, rates of toxicity seem higher with brexu-cel.